Impact of physicochemical profiling for rational approach on drug discovery

Chemical and Pharmaceutical Bulletin

Volumn 61, Issue 12, 2013, Pages 1228-1238

  Nakashima, Shoko ^a   Yamamoto, Katsuhiko ^a   Arai, Yuta ^a   Ikeda, Yukihiro ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Bioavailability; Kinetic solubility; Lipophilicity; Physicochemistry; Thermodynamic solubility

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; ANASTROZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; AURORA KINASE INHIBITOR; BICALUTAMIDE; CHIR 265; CRIZOTINIB; DOCETAXEL; ERLOTINIB; FLUTAMIDE; HISTONE DEACETYLASE INHIBITOR; HYDROXYFLUTAMIDE; IDARUBICIN; LETROZOLE; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NUTLIN 3; PACLITAXEL; RIGOSERTIB; ROSIGLITAZONE; SORAFENIB; SOTRASTAURIN; SUNITINIB; TACROLIMUS; TOPOTECAN; TROGLITAZONE; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG SOLUBILITY; ENERGY; GASTROINTESTINAL ABSORPTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROGEN BOND; INTESTINE FLUID; LIPOPHILICITY; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PH; PHYSICAL CHEMISTRY; RAT; SIMULATION; SOLID STATE; TANDEM MASS SPECTROMETRY; THERMODYNAMICS;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CRYSTALLIZATION; DRUG DISCOVERY; MALE; NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; THERMODYNAMICS;

EID: 84890097215     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.c13-00436     Document Type: Article

References (42)

1. Colombo P., Sonvico F., Colombo G., Bettini R., Pharm. Res., 26, 601-611 (2009).
2. Helliwell M., Taylor D., Prof. Nurse, 8, 313-317 (1993).
3. Lipinski C. A., J. Pharmacol. Toxicol. Methods, 44, 235-249 (2000).
4. Stegemann S., Leveiller F., Franchi D., de Jong H., Lindén H., Eur. J. Pharm. Sci., 31, 249-261 (2007).
5. Lipinski C. A., Lombardo F., Dominy B. W., Feeney P. J., Adv. Drug Deliv. Rev., 46, 3-26 (2001).
6. Brittain H. G., "Polymorphism in Pharmaceutical Solids," 2nd ed., Marcel Dekker, New York, 1999.
7. Byrn S. R., Pfeiffer R. R., Stowell J. G., "Solid State Chemistry of Drugs," 2nd ed., SSCI Incorporation, West Lafayette, 1999.
8. Haleblian J. K., J. Pharm. Sci., 64, 1269-1288 (1975).
9. Singh D., Marshall P. V., Shields L., York P., J. Pharm. Sci., 87, 655-662 (1998).
10. Pudipeddi M., Serajuddin A. T., J. Pharm. Sci., 94, 929-939 (2005).
11. Lipinski C. A., "Pharmaceutical profiling in drug discovery for lead selection," ed. by Borchardt R.T., Kerns E.H., Lipinski C.A., Thakker D.R., Wang B., AAPS Press, Arlington, Virginia, 2004, pp. 93-125.
12. Saal C., Petereit A. C., Eur. J. Pharm. Sci., 47, 589-595 (2012).
13. Lipinski C. A., Drug Discov. Today Technol., 1, 337-341 (2004).
14. Congreve M., Carr R., Murray C., Jhoti H., Drug Discov. Today, 8, 876-877 (2003).
15. Didziapetris R., Japertas P., Avdeef A., Petrauskas A., J. Drug Target., 11, 391-406 (2003).
16. Wang J., Hou T., Comb. Chem. High Throughput Screen., 14, 328-338 (2011).
17. Zhang L., Zhu H., Mathiowetz A., Gao H., Bioorg. Med. Chem., 19, 5763-5770 (2011).
18. Ali J., Camilleri P., Brown M. B., Hutt A. J., Kirton S. B., J. Chem. Inf. Model., 52, 420-428 (2012).
19. Ritchie T. J., Macdonald S. J., Young R. J., Pickett S. D., Drug Discov. Today, 16, 164-171 (2011).
20. Thomas V. H., Bhattachar S., Hitchingham L., Zocharski P., Naath M., Surendran N., Stoner C. L., El-Kattan A., Expert Opin. Drug Metab. Toxicol., 2, 591-608 (2006).
21. Wassvik C. M., Holmén A. G., Bergström C. A., Zamora I., Artursson P., Eur. J. Pharm. Sci., 29, 294-305 (2006).
22. Cheng A., Merz K. M. Jr., J. Med. Chem., 46, 3572-3580 (2003).
23. Yang Y., Engkvist O., Llinàs A., Chen H., J. Med. Chem., 55, 3667-3677 (2012).
24. Di L., Fish P. V., Mano T., Drug Discov. Today, 17, 486-495 (2012).
25. Hermans P. H., Weidinger A., J. Appl. Phys., 19, 491-506 (1948).
26. Ikeda Y., Ban J., Ishikawa T., Hashiguchi S., Urayama S., Horibe H., Chem. Pharm. Bull., 56, 1406-1411 (2008).
27. Yamamura S., Momose Y., Int. J. Pharm., 212, 203-212 (2001).
28. Hoelke B., Gieringer S., Arlt M., Saal C., Anal. Chem., 81, 3165-3172 (2009).
29. Komura H., Kawahara I., Shigemoto Y., Matsuda K., Ano R., Murayama Y., Moriwaki T., Yoshida N. H., Yakugaku Zasshi, 125, 121-130 (2005).
30. Masumoto K., Takeyasu A., Oizumi K., Kobayashi T., Yakugaku Zasshi, 115, 213-220 (1995).
31. He K., Qian M., Wong H., Bai S. A., He B., Brogdon B., Grace J. E., Xin B., Wu J., Ren S. X., Zeng H., Deng Y., Graden D. M., Olah T. V., Unger S. E., Luettgen J. M., Knabb R. M., Pinto D. J., Lam P. Y., Duan J., Wexler R. R., Decicco C. P., Christ D. D., Grossman S. J., J. Pharm. Sci., 97, 2568-2580 (2008).
32. Nagilla R., Nord M., McAtee J. J., Jolivette L. J., J. Pharm. Sci., 100, 3862-3874 (2011).
33. Sugaya Y., Yoshiba T., Kajima T., Ishihama Y., Yakugaku Zasshi, 122, 237-246 (2002).
34. Ku M. S., "Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice," Chap. 4, ed. by Wen H., Park K., John Wiley & Sons, Inc., Hoboken, NJ, U.S.A., 2010, pp. 47-70.
35. Toke O., Monsey J. D., DeKoster G. T., Tochtrop G. P., Tang C., Cistola D. P., Biochemistry, 45, 727-737 (2006).
36. Guha R., Dexheimer T. S., Kestranek A. N., Jadhav A., Chervenak A. M., Ford M. G., Simeonov A., Roth G. P., Thomas C. J., Bioorg. Med. Chem., 19, 4127-4134 (2011).
37. Hill A. P., Young R. J., Drug Discov. Today, 15, 648-655 (2010).
38. Obata K., Sugano K., Saitoh R., Higashida A., Nabuchi Y., Machida M., Aso Y., Int. J. Pharm., 293, 183-192 (2005).
39. Lovering F., Bikker J., Humblet C., J. Med. Chem., 52, 6752-6756 (2009).
40. Leach A. G., Jones H. D., Cosgrove D. A., Kenny P. W., Ruston L., MacFaul P., Wood J. M., Colclough N., Law B., J. Med. Chem., 49, 6672-6682 (2006).
41. Schultes S., de Graaf C., Berger H., Mayer M., Steffen A., Haaksma E. E. J., de Esch I. J. P., Leursb R., Krämer O., Med. Chem. Commun., 3, 584-591 (2012).
42. Mithani S. D., Bakatselou V., TenHoor C. N., Dressman J. B., Pharm. Res., 13, 163-167 (1996).